Gene · 6007
Papers4,511
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
621 to 640 of 4,511
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The shared genetic landscape of blood cell traits and risk of neurological and psychiatric disorders. | Cell Genom | 2023 | 36819664 | PubTator, text mining | PubMed |
| Renal function protection and the mechanism of ginsenosides: Current progress and future perspectives. | Front Pharmacol | 2023 | 36814491 | PubTator, text mining | PubMed |
| ABO Blood Groups and Incidence of COVID-19 in the Mass Gathering Events in Borriana (Spain), March 2020: A Retrospective Cohort Study. | Epidemiologia (Basel) | 2023 | 36810454 | PubTator, text mining | PubMed |
| The females have spoken: A patient-centered national survey on the administration of emergent transfusions with the potential for future fetal harm. | J Trauma Acute Care Surg | 2023 | 36808128 | PubTator, text mining | PubMed |
| Evaluation of an automated platform for non-invasive single-exon fetal RHD genotyping early in pregnancy. | Blood Transfus | 2023 | 36795345 | PubTator, text mining | PubMed |
| CDKAL1 Drives the Maintenance of Cancer Stem-Like Cells by Assembling the eIF4F Translation Initiation Complex. | Adv Sci (Weinh) | 2023 | 36786012 | PubTator, text mining | PubMed |
| An education resource for human papillomavirus oropharyngeal cancer patients: think-aloud interviews. | Support Care Cancer | 2023 | 36773108 | PubTator, text mining | PubMed |
| The Cytotoxic Effect of Curcumin in Rhabdomyosarcoma Is Associated with the Modulation of AMPK, AKT/mTOR, STAT, and p53 Signaling. | Nutrients | 2023 | 36771452 | PubTator, text mining | PubMed |
| Targeted Sequencing Approach and Its Clinical Applications for the Molecular Diagnosis of Human Diseases. | Cells | 2023 | 36766834 | PubTator, text mining | PubMed |
| The modulation of iron metabolism affects the Rhabdomyosarcoma tumor growth in vitro and in vivo. | Clin Exp Med | 2023 | 36764998 | PubTator, text mining | PubMed |
| Association of blood group with COVID-19 disease susceptibility and severity in Saudi Arabia. | Transfusion | 2023 | 36748669 | PubTator, text mining | PubMed |
| Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide. | Clin Epigenetics | 2023 | 36740715 | PubTator, text mining | PubMed |
| Addressing ethical issues related to prenatal diagnostic procedures. | Matern Health Neonatol Perinatol | 2023 | 36737803 | PubTator, text mining | PubMed |
| Establishing pregnancy-specific haematological reference intervals in Ghana; a three-center cross-sectional study. | PLoS One | 2023 | 36735666 | PubTator, text mining | PubMed |
| Alloantigen Copy Number as a Critical Factor in RBC Alloimmunization. | Transfus Med Rev | 2023 | 36725483 | PubTator, text mining | PubMed |
| Transfusion management of Africans with RHD variants in China. | Transfus Clin Biol | 2023 | 36702201 | PubTator, text mining | PubMed |
| Characteristics of Donors and Modelling of the Characteristics to Possible Forecast the Repeat Donors Profile at Thammasat University Hospital. | Indian J Hematol Blood Transfus | 2023 | 36699423 | PubTator, text mining | PubMed |
| Prevalence of ABO and Rh Blood Group Among Volunteer Blood Donors at the Blood and Tissue Bank Service in Addis Ababa, Ethiopia. | J Blood Med | 2023 | 36698774 | PubTator, text mining | PubMed |
| Zebrafish her3 knockout impacts developmental and cancer-related gene signatures. | Dev Biol | 2023 | 36696714 | PubTator, text mining | PubMed |
| Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma. | Mol Cancer Ther | 2023 | 36696581 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6007/papers?page=32